Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 4/20 | 1.00 |
| ▸ | MEN1 | O00255 | 3/20 | 1.00 |
| ▸ | HTT | P42858 | 2/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 14/20 | 0.71 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.71 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.71 |
| ▸ | POLB | P06746 | 1/20 | 0.70 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.65 |
| ▸ | GAA | P10253 | 1/20 | 0.65 |
| ▸ | TSHR | P16473 | 2/20 | 0.61 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22426227 | 0.76 | POLB (0.72) | SMN1; SMN2KMT2AMEN1HTTALDH1A1 | |
| SCHEMBL22426228 | 0.76 | POLB (0.72) | SMN1; SMN2KMT2AMEN1HTTALDH1A1 | |
| SCHEMBL2316901 | 0.75 | CYP2D6 (0.82) | KMT2AMEN1ALDH1A1HSD17B10MAPK1 | |
| SCHEMBL24323848 | 0.73 | GAA (0.82) | SMN1; SMN2KMT2AMEN1HTTALDH1A1 | |
| SCHEMBL8175092 | 0.72 | HSD17B10 (0.71) | SMN1; SMN2KMT2AMEN1ALDH1A1NPSR1 | |
| SCHEMBL108678 | 0.71 | KDM4E (0.70) | KMT2AMEN1HSD17B10MAPK1TSHR | |
| SCHEMBL1299628 | 0.69 | SIGMAR1 (0.61) | — | |
| SCHEMBL12237371 | 0.69 | KDM4E (0.76) | SMN1; SMN2KMT2AMEN1ALDH1A1NPSR1 | |
| SCHEMBL3129023 | 0.69 | ALDH1A1 (0.69) | KMT2AMEN1HTTALDH1A1POLB | |
| SCHEMBL27663745 | 0.69 | SLC18A3 (0.63) | SMN1; SMN2KMT2AMEN1ALDH1A1NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200071735-A1 | Compounds for Increasing Lipid Synthesis and Storage | WASE, NISHIKANT | 2020-03-05 | — | — | US | disclosed |
| US-10351883-B2 | Compounds for increasing lipid synthesis and storage | NUTECH VENTURES (US) | 2019-07-16 | — | — | US | disclosed |
| US-20160312253-A1 | Compounds for Increasing Lipid Synthesis and Storage | INVITROGEN CORPORATION | 2016-10-27 | — | — | US | disclosed |
| US-20160312253-A1 | Compounds for Increasing Lipid Synthesis and Storage | INVITROGEN CORPORATION | 2016-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160312253-A1 | Compounds for Increasing Lipid Synthesis and Storage | FASN, LIPC, SREBF2 | SMN1; SMN2 4517/4885KMT2A 2512/4885MEN1 2824/4885 |
| US-10351883-B2 | Compounds for increasing lipid synthesis and storage | FASN, LIPC, SREBF2 | SMN1; SMN2 4517/4885KMT2A 2512/4885MEN1 2824/4885 |
| US-20200071735-A1 | Compounds for Increasing Lipid Synthesis and Storage | FASN, LIPC, SREBF2 | SMN1; SMN2 4517/4885KMT2A 2512/4885MEN1 2824/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.